Emergency contraception with mifepristone
20. September 2018 (online)
Study of efficacy and possible complications following administration of mifepristone to women who reported unprotected sexual intercourse or where protective measures failed (emergency contraception).
Material and method:
We administered 100 mg of mifepristone to 40 women who reported intercourse without taking precautions between January 2010 and December 2014, and we evaluated them clinically and in the laboratory for a month with respect to: – The appearance or not of pregnancy, disturbances in the upcoming menstruation and side effects as well as the severity of these side effects.
On the day of administration of mifepristone we performed transvaginal ultrasound as well as measurement of β-hCG, LH, estradiol, serum progesterone. The same tests were repeated each week until the onset of the coming menstruation.
No pregnancy occurred. Successive, weekly β-hCG measurements were all negative as well as ultrasonographic testing. In 9 women in the mid luteal phase (PRG> 2.0 ng/ml), metrorrhagia and normal menstruation occurred after 10 – 12 days.
In 31 women who were in a follicular phase (PRG < 1.5 ng/ml), menstruation was delayed by 3 – 4 days due to prolonged ovulation.
None of the women experienced any quantitative/qualitative changes in the character of menstruation.
Adverse events such as nausea, vomiting and abdominal pain have occurred. No treatment was nessecary.
Close and added to established and accepted methods of emergency contraception, is that of administering an average dose of mifepristone which exhibits high rates of success, safety, low level of adverse effects and similar costs.